Ruchi Saxena

5PUBLICATIONS
19CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsReaction engineering (excl. nuclear reactions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 03, 2025
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Jeffrey M Clarke, George R Simon, Hirva Mamdani

|Apr 01, 2024
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.

Ruchi Saxena, Ryan T Bushey, Michael J Campa

|Mar 30, 2023
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103.

Ryan T Bushey, Ruchi Saxena, Michael J Campa

|Jan 21, 2021
ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma.

Prateek Khanna, Hong Jie Soh, Chun-Hau Chen

Pageof 1